Cargando…

Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C–induced HIV latency reversal

Latency-reversing agents (LRAs) are considered a potential strategy for curing cells of HIV-1 infection. Certain protein kinase C (PKC) activators have been previously reported to be LRAs because they can reverse HIV latency. In the present study, we examined the activities of a panel of benzolactam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuda, Kouki, Kobayakawa, Takuya, Tsuchiya, Kiyoto, Hattori, Shin-ichiro, Nomura, Wataru, Gatanaga, Hiroyuki, Yoshimura, Kazuhisa, Oka, Shinichi, Endo, Yasuyuki, Tamamura, Hirokazu, Mitsuya, Hiroaki, Maeda, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2019
Materias:	Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322896/ https://www.ncbi.nlm.nih.gov/pubmed/30413535 http://dx.doi.org/10.1074/jbc.RA118.005798

Ejemplares similares

Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro
por: Hattori, Shin-ichiro, et al.
Publicado: (2018)

A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators
por: Matsuda, Kouki, et al.
Publicado: (2021)

A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro
por: Matsuda, Kouki, et al.
Publicado: (2021)

Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants
por: Tsuchiya, Kiyoto, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
por: Maeda, Kenji, et al.
Publicado: (2021)

Assessing the effects of antiretroviral therapy-latency-reversing agent combination therapy on eradicating replication-competent HIV provirus in a Jurkat cell culture model
por: Matsuda, Kouki, et al.
Publicado: (2023)

Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication
por: Maeda, Kenji, et al.
Publicado: (2019)

Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors
por: Hayashida, Tsunefusa, et al.
Publicado: (2017)

Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism
por: Tsuchiya, Kiyoto, et al.
Publicado: (2013)

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine
por: Yasutake, Yoshiaki, et al.
Publicado: (2020)

Pharmacokinetics of Bictegravir in Older Japanese People Living with HIV-1
por: Kawashima, Akira, et al.
Publicado: (2023)

Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s
por: Nakata, Hirotomo, et al.
Publicado: (2019)

Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins
por: Kobayakawa, Takuya, et al.
Publicado: (2023)

Illicit Drug Use Is a Significant Risk Factor for Loss to Follow Up in Patients with HIV-1 Infection at a Large Urban HIV Clinic in Tokyo
por: Nishijima, Takeshi, et al.
Publicado: (2013)

HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir
por: Yasutake, Yoshiaki, et al.
Publicado: (2018)

Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection
por: Nishijima, Takeshi, et al.
Publicado: (2014)

High Prevalence of Illicit Drug Use in Men Who Have Sex with Men with HIV-1 Infection in Japan
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins
por: Kobayakawa, Takuya, et al.
Publicado: (2021)

Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals
por: Maeda, Kenji, et al.
Publicado: (2021)

Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
por: Maeda, Kenji, et al.
Publicado: (2021)

Epigenetic Heterogeneity in HIV-1 Latency Establishment
por: Matsuda, Yuka, et al.
Publicado: (2015)

The second molecular epidemiological study of HIV infection in Mongolia between 2010 and 2016
por: Jagdagsuren, Davaalkham, et al.
Publicado: (2017)

Bioinformatics and HIV Latency
por: Ciuffi, Angela, et al.
Publicado: (2015)

Role of Escape Mutant-Specific T Cells in Suppression of HIV-1 Replication and Coevolution with HIV-1
por: Zhang, Yu, et al.
Publicado: (2020)

A cell cycle-dependent CRISPR-Cas9 activation system based on an anti-CRISPR protein shows improved genome editing accuracy
por: Matsumoto, Daisuke, et al.
Publicado: (2020)

HIV-1 protective epitope-specific CD8(+) T cells in HIV-1-exposed seronegative individuals
por: Chikata, Takayuki, et al.
Publicado: (2023)

Slow Turnover of HIV-1 Receptors on Quiescent CD4(+) T Cells Causes Prolonged Surface Retention of gp120 Immune Complexes In Vivo
por: Suzuki, Yasuhiro, et al.
Publicado: (2014)

Control of HIV-1 by multiple immunodominant HIV-1-specific CD8+ T cells in HIV-1-infected Japanese individuals
por: Murakoshi, H, et al.
Publicado: (2012)

Cerebral Syphilitic Gumma within 5 Months of Syphilis in HIV-Infected Patient
por: Tsuboi, Motoyuki, et al.
Publicado: (2016)

P16-06. Control of HIV-1 by HIV-1 Pol-specific CD8+ T cells in chronically HIV-1-infected Japanese cohort
por: Murakoshi, H, et al.
Publicado: (2009)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

The BAF complex and HIV latency
por: Mahmoudi, Tokameh
Publicado: (2012)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

Amebiasis in HIV-1-Infected Japanese Men: Clinical Features and Response to Therapy
por: Watanabe, Koji, et al.
Publicado: (2011)

Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele
por: Zhang, Yu, et al.
Publicado: (2022)

Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
por: Tamamura, Hirokazu, et al.
Publicado: (2008)

Epitope-dependent effect of long-term cART on maintenance and recovery of HIV-1-specific CD8(+) T cells
por: Kuse, Nozomi, et al.
Publicado: (2023)

Nation-Wide Viral Sequence Analysis of HIV-1 Subtype B Epidemic in 2003–2012 Revealed a Contribution of Men Who Have Sex With Men to the Transmission Cluster Formation and Growth in Japan
por: Shiino, Teiichiro, et al.
Publicado: (2020)

Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2–Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan
por: Amano, Masayuki, et al.
Publicado: (2022)

What Triggers a Diagnosis of HIV Infection in the Tokyo Metropolitan Area? Implications for Preventing the Spread of HIV Infection in Japan
por: Nishijima, Takeshi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_31rauj6ckhnnavhomcdnai5ko1